Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Dec 29, 2023
- Accession no.
- 0001447362-23-000194
- Filed
- Dec 29, 2023
- Trade date
- Dec 27-28, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 14 non-derivative transactions. Open-market sales total $301.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 27, 2023 | Common Stock | SSaleDisposed | −8,076 | $21.90F2 | −$176,864.4 | 68,038 | Direct | |
| Dec 27, 2023 | Common Stock | SSaleDisposed | −329 | $21.90F2 | −$7,205.1 | 92,246 | Indirect | |
| Dec 27, 2023 | Common Stock | SSaleDisposed | −329 | $21.90F2 | −$7,205.1 | 81,141 | Indirect | |
| Dec 27, 2023 | Common Stock | SSaleDisposed | −122 | $21.90F2 | −$2,671.8 | 11,696 | Indirect | |
| Dec 27, 2023 | Common Stock | SSaleDisposed | −119 | $21.90F2 | −$2,606.1 | 11,694 | Indirect | |
| Dec 27, 2023 | Common Stock | SSaleDisposed | −119 | $21.90F2 | −$2,606.1 | 11,693 | Indirect | |
| Dec 27, 2023 | Common Stock | SSaleDisposed | −119 | $21.90F2 | −$2,606.1 | 11,688 | Indirect | |
| Dec 28, 2023 | Common Stock | SSaleDisposed | −3,954 | $22.17F9 | −$87,660.18 | 64,084 | Direct | |
| Dec 28, 2023 | Common Stock | SSaleDisposed | −161 | $22.17F9 | −$3,569.37 | 92,085 | Indirect | |
| Dec 28, 2023 | Common Stock | SSaleDisposed | −161 | $22.17F9 | −$3,569.37 | 80,980 | Indirect | |
| Dec 28, 2023 | Common Stock | SSaleDisposed | −58 | $22.17F9 | −$1,285.86 | 11,638 | Indirect | |
| Dec 28, 2023 | Common Stock | SSaleDisposed | −59 | $22.17F9 | −$1,308.03 | 11,635 | Indirect | |
| Dec 28, 2023 | Common Stock | SSaleDisposed | −59 | $22.17F9 | −$1,308.03 | 11,634 | Indirect | |
| Dec 28, 2023 | Common Stock | SSaleDisposed | −59 | $22.17F9 | −$1,308.03 | 11,629 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $21.83 to $22.05, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $22.12 to $22.27, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.